Guangzhou Xinjie Pharmaceutical Technology

Guangzhou Xinjie Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Guangzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology. The company's lead candidate, XJ-001, is a potent and selective inhibitor of Ubiquitin-Specific Peptidase 1 (USP1), currently undergoing Phase 1/2 clinical trials for the treatment of advanced solid tumors, particularly those with homologous recombination deficiency (HRD). Xinjie Pharma leverages its expertise in medicinal chemistry and the ubiquitin-proteasome system (UPS) to build a pipeline of targeted therapies. The company aims to provide novel treatment options for cancer patients who have developed resistance to existing therapies such as PARP inhibitors. Its research strategy emphasizes the DNA damage response (DDR) pathway to address high unmet medical needs in cancer care.